AMD 3465 (hexahydrobromide)

AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.

Product Specifications

CAS Number

[185991-07-5]

Product Name Alternative

GENZ-644494 (hexahydrobromide)

UNSPSC

12352005

Target

CXCR; HIV

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection; Endocrinology

Assay Protocol

https://www.medchemexpress.com/AMD-3465-hexahydrobromide.html

Purity

98.0

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : ≥ 38 mg/mL

Smiles

[H]Br.[H]Br.[H]Br.[H]Br.[H]Br.[H]Br.C1(CNCC2=CC=C(CN3CCNCCCNCCNCCC3)C=C2)=NC=CC=C1

Molecular Formula

C24H44Br6N6

Molecular Weight

896.07

References & Citations

[1]Hatse S, et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol. 2005 Sep 1;70 (5) :752-61.|[2]Yang L, et al. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007 Jan 15;67 (2) :651-8.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

CXCR4; HIV-1; HIV-2

Citation 01

Biomed Pharmacother. 2021 Jun:138:111476.|Immunity. 2025 Aug 12:S1074-7613 (25) 00314-0.|J Labelled Comp Radiopharm. 2018 May 15;61 (5) :438-446. |Patent. US20180263995A1.|Br J Haematol. 2023 May;201 (3) :459-469.